Niagen Bioscience, Inc. - Common Stock (NAGE)
Healthcare › Medicinal Chemicals & Botanical Products
Price History
Feb 9, 2026 — Apr 1, 2026Investment Snapshot
- Trading 119% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 19.8% — good return on equity
- Revenue growing at 30% annually
Niagen Bioscience, Inc. - Common Stock (NAGE) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NASDAQ , with a market capitalisation of $353 million . Key value metrics: P/E ratio 23.3, P/B ratio 4.61, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Niagen Bioscience, Inc. - Common Stock — Fundamental Analysis Summary
Niagen Bioscience, Inc. - Common Stock (NAGE) is currently trading 119% above its Graham Number of $2.02, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 23.3x.
On financial health, NAGE shows a moderate Piotroski F-Score of 5/9, and solid return on equity of 19.8% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.39.
StockPik's composite Value Score for NAGE is 81/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
NAGE reports a high gross margin of 64.1% (sector average: 33.5%) and a solid operating margin of 11.4%.
NAGE shows revenue growing at 30% year-over-year, with earnings growing at 103%.